… 0.60) mHSPC. The incidence of all adverse events (AE … ), including the incidence of serious and grade 3 … in mHSPC where the incidences of adverse events were … eventually progress to castration-resistant prostate cancer (CRPC), a condition with …

… with with metastatic hormone-sensitive prostate cancer (mHSPC), Nubeqa (darolutamide) and … being, functional well-being, and prostate cancer concerns, including urinary symptoms. … months for the placebo group. Incidence of treatment-emergent side effects …

… patients with metastatic castration-sensitive prostate cancer (mCSPC), also known as … men were diagnosed with prostate cancer, and global incidence is expected to rise … and non-metastatic castration-resistant prostate cancer (nmCRPC), offering a broader …

… patients with metastatic castration-sensitive prostate cancer (mCSPC), which is … across various stages of prostate cancer, underscoring our commitment to … 0.60) mHSPC. The incidence of all adverse events … (AE), including the incidence of serious and grade …

… 8%), with relatively low incidences of serious adverse effects overall … patients with metastatic castration-sensitive prostate cancer receiving Nubeqa (darolutamide) plus … darolutamide for metastatic castration-sensitive prostate cancer. OncLive®. June 3, 2025 …

… incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer … . Buzzoni C, et al. Metastatic prostate cancer incidence and prostate-specific antigen testing … -890. Siegel DA, et al. Prostate cancer incidence and survival, by stage and …

… PSA freedom from biochemical failure, prostate cancer-specific outcomes, and OS. The … .2% experienced headaches. Additionally, the incidence of treatment-related serious AEs … . In the respective arms, the incidence of AE-related treatment discontinuation …

… patients with metastatic hormone-sensitive prostate cancer (mHSPC), including clinically meaningful … , functional well-being, and prostate cancer concerns, including urinary symptoms. … for the placebo group. Incidence of treatment-emergent adverse events …

… tolerability profile of darolutamide for prostate cancer patients across all approved indications … .15-0.60) mHSPC. The incidence of adverse events in the … eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited …

… will experience prostate cancer during their lifetime. And the incidence rate has increased … experiencing the highest rates of prostate cancer. Yet with intervention, the … for many men living with prostate cancer, lifestyle adjustments involve limitations in …